The NanoAssemblr Blaze is enabling for researchers and drug development programs. The dynamic volume range allows researchers to use the Blaze for nanoparticle discovery, preclinical toxicology testing and for early Chemistry, Manufacturing and Controls (CMC) studies.

Precision NanoSystems Launches the NanoAssemblr Blaze

Precision NanoSystems to Advance Large-Scale Production of Nanoparticles with its NanoAssemblr Blaze System

Vancouver, BC, August 18, 2016 – Precision NanoSystems, Inc. (PNI), a biotechnology company dedicated to helping advance innovative nanotechnology solutions for the molecular understanding and treatment of disease, today officially launches its NanoAssemblr Blaze™ system.

The NanoAssemblr Blaze moves nanomedicine development from the preliminary stages of formulation screening and iteration onto large batch manufacturing of nanoparticles suitable for toxicology screening and analysis. Based on the proven NanoAssemblr platform, the increase in volume afforded by the Blaze provides a seamless transition without further process development.

“This product is an exciting leap forward for Precision NanoSystems,” said James Taylor, CEO and Co-founder of PNI. “We started with our NanoAssemblr Benchtop instrument, which helped researchers develop small batches of precise nanoparticles, but we soon realized we needed to respond to the impetus to scale up production with that same level of accuracy. TheNanoAssemblr Blaze does exactly that, without having to re-invent process.”

The NanoAssemblr Blaze utilizes the latest microfluidic technology with continuous flow pumping through a proprietary microfluidic cartridge to produce large volumes of identical nanoparticles, between 10 mL and 1 L per batch. The process ensures the self-assembly of uniform particles with controllable and reproducible results.

PNI Chief Operating Officer Euan Ramsay says the system is perfect for nanomedicine candidate selection and early CMC investigation. “The NanoAssemblr Blaze gives scientists the ability to scale up their experiments and accelerate discovery,” said Ramsay. “We anticipate a leap forward in research results and thus the ultimate treatment of disease using nanoparticle-based medicine.”

Researchers can now create scalable amounts of nanoparticles – with significant cost and labor reductions – and with the certainty that the product has been made to the highest of standards. The NanoAssemblr Blaze brings large batch nanoparticle studies in-house, and transfers small or lab-scale formulations seamlessly into large volumes.